arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ANI PHARMACEUTICALS INC

ANIP
$78.35 ▼ -4.24 (-5.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
71
Health
Good
Bullish
auto_awesome

Analytical Summary

ANI PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.6B
Dividend Yield
Revenue Growth 20.5%
Op. Margin 16.4%
ROIC 3.4%
FCF / Share $2.50
Trailing P/E 59.8x
Price / Book 2.9x
FCF Yield 3.2%
Debt / Equity 0.51
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$237.46M
↑ +20.5%
Net Income Profit after all expenses
$29.49M
↑ +88.1%
Operating Margin Operating profit as % of sales
16.4%
↑ +16.4% 62th
FCF / Share Free cash flow per share
$2.50
↑ +50.8%
Long-Term Debt Long-term obligations
$286.00M
↓ -2.0%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
68
Returns
79
Financial Health
58
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters